482 related articles for article (PubMed ID: 15303780)
21. Clobetasol propionate 0.05% in a novel foam formulation is safe and effective in the short-term treatment of patients with delayed pressure urticaria: a randomized, double-blind, placebo-controlled trial.
Vena GA; Cassano N; D'Argento V; Milani M
Br J Dermatol; 2006 Feb; 154(2):353-6. PubMed ID: 16433809
[TBL] [Abstract][Full Text] [Related]
22. A randomized, double-blind, placebo-controlled study of clobetasol propionate 0.05% foam in the treatment of nonscalp psoriasis.
Lebwohl M; Sherer D; Washenik K; Krueger GG; Menter A; Koo J; Feldman SR
Int J Dermatol; 2002 May; 41(5):269-74. PubMed ID: 12100701
[TBL] [Abstract][Full Text] [Related]
23. Clobetasol propionate for psoriasis: are ointments really more potent?
Warino L; Balkrishnan R; Feldman SR
J Drugs Dermatol; 2006 Jun; 5(6):527-32. PubMed ID: 16774104
[TBL] [Abstract][Full Text] [Related]
24. A new scalp formulation of calcipotriene plus betamethasone compared with its active ingredients and the vehicle in the treatment of scalp psoriasis: a randomized, double-blind, controlled trial.
Jemec GB; Ganslandt C; Ortonne JP; Poulin Y; Burden AD; de Unamuno P; Berne B; Figueiredo A; Austad J
J Am Acad Dermatol; 2008 Sep; 59(3):455-63. PubMed ID: 18694678
[TBL] [Abstract][Full Text] [Related]
25. Nail psoriasis: a combined treatment with 8% clobetasol nail lacquer and tacalcitol ointment.
Sánchez Regaña M; Márquez Balbás G; Umbert Millet P
J Eur Acad Dermatol Venereol; 2008 Aug; 22(8):963-9. PubMed ID: 18410337
[TBL] [Abstract][Full Text] [Related]
26. Clobetasol propionate spray 0.05% add-on therapy to a stable regimen of biologic treatment in patients with moderate to very severe plaque psoriasis.
Feldman SR; Koo JY; Johnson LA; Preston NJ
Cutis; 2009 Oct; 84(4 Suppl):25-32. PubMed ID: 19916299
[TBL] [Abstract][Full Text] [Related]
27. Cost-effectiveness evaluation of clobetasol propionate shampoo (CPS) maintenance in patients with moderate scalp psoriasis: a Pan-European analysis.
Papp K; Poulin Y; Barber K; Lynde C; Prinz JC; Berg M; Kerrouche N; Rives VP
J Eur Acad Dermatol Venereol; 2012 Nov; 26(11):1407-14. PubMed ID: 22032474
[TBL] [Abstract][Full Text] [Related]
28. A new scalp formulation of calcipotriol plus betamethasone dipropionate compared with each of its active ingredients in the same vehicle for the treatment of scalp psoriasis: a randomized, double-blind, controlled trial.
van de Kerkhof PC; Hoffmann V; Anstey A; Barnes L; Bolduc C; Reich K; Saari S; Segaert S; Vaillant L
Br J Dermatol; 2009 Jan; 160(1):170-6. PubMed ID: 19067709
[TBL] [Abstract][Full Text] [Related]
29. Clobetasol propionate foam 0.05% as a novel topical formulation for plaque-type and scalp psoriasis.
Mazzotta A; Esposito M; Carboni I; Schipani C; Chimenti S
J Dermatolog Treat; 2007; 18(2):84-7. PubMed ID: 17520464
[TBL] [Abstract][Full Text] [Related]
30. Comparing clobetasol propionate 0.05% spray to calcipotriene 0.005% betamethasone dipropionate 0.064% ointment for the treatment of moderate to severe plaque psoriasis.
Menter A; Abramovits W; Colón LE; Johnson LA; Gottschalk RW
J Drugs Dermatol; 2009 Jan; 8(1):52-7. PubMed ID: 19180896
[TBL] [Abstract][Full Text] [Related]
31. Scalp psoriasis.
Kircik LH; Kumar S
J Drugs Dermatol; 2010 Aug; 9(8 Suppl ODAC Conf Pt 2):s101-5. PubMed ID: 20715392
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and safety of twice-daily augmented betamethasone dipropionate lotion versus clobetasol propionate solution in patients with moderate-to-severe scalp psoriasis.
Katz HI; Lindholm JS; Weiss JS; Shavin JS; Morman M; Bressinck R; Cornell R; Pariser DM; Pariser RJ; Weng W
Clin Ther; 1995; 17(3):390-401. PubMed ID: 7585843
[TBL] [Abstract][Full Text] [Related]
33. Clinical studies of a new vehicle formulation for topical corticosteroids in the treatment of psoriasis.
Stein L
J Am Acad Dermatol; 2005 Jul; 53(1 Suppl 1):S39-49. PubMed ID: 15968263
[TBL] [Abstract][Full Text] [Related]
34. Calcipotriol plus betamethasone dipropionate scalp formulation is effective and well tolerated in the treatment of scalp psoriasis: a phase II study.
Buckley C; Hoffmann V; Shapiro J; Saari S; Cambazard F; Milsgaard M
Dermatology; 2008; 217(2):107-13. PubMed ID: 18463448
[TBL] [Abstract][Full Text] [Related]
35. Clobetasol propionate 0.05% lotion in the treatment of moderate to severe atopic dermatitis: a randomized evaluation versus clobetasol propionate emollient cream.
Breneman D; Fleischer AB; Kaplan D; Lebwohl M; Miller B; Pariser D; Rist T; Swinyer L; Liu Y; Foley V
J Drugs Dermatol; 2005; 4(3):330-6. PubMed ID: 15898289
[TBL] [Abstract][Full Text] [Related]
36. A double-blind, vehicle-controlled study of clobetasol propionate 0.05% (Temovate) scalp application in the treatment of moderate to severe scalp psoriasis.
Olsen EA; Cram DL; Ellis CN; Hickman JG; Jacobson C; Jenkins EE; Lasser AE; Lebwohl M; Leibsohn E; Medansky RS
J Am Acad Dermatol; 1991 Mar; 24(3):443-7. PubMed ID: 2061442
[TBL] [Abstract][Full Text] [Related]
37. A lipohydroxyacid-containing shampoo improves scalp condition and quality of life in patients with seborrheic dermatitis and light-to-moderate scalp psoriasis.
Seité S; Paries J; Reygagne P; Hamidou Z; Jouanique C; Perez-Pala G; Rougier A
J Cosmet Dermatol; 2009 Jun; 8(2):108-13. PubMed ID: 19527334
[TBL] [Abstract][Full Text] [Related]
38. Impact of clobetasol propionate 0.05% spray on health-related quality of life in patients with plaque psoriasis.
Menter MA; Caveney SW; Gottschalk RW
J Drugs Dermatol; 2012 Nov; 11(11):1348-54. PubMed ID: 23135087
[TBL] [Abstract][Full Text] [Related]
39. Fluocinolone acetonide topical oil for scalp psoriasis.
Pauporte M; Maibach H; Lowe N; Pugliese M; Friedman DJ; Mendelsohn H; Cargill I; Ramirez R
J Dermatolog Treat; 2004 Dec; 15(6):360-4. PubMed ID: 15764047
[TBL] [Abstract][Full Text] [Related]
40. The evolving role of therapeutic shampoos for targeting symptoms of inflammatory scalp disorders.
Kircik L
J Drugs Dermatol; 2010 Jan; 9(1):41-8. PubMed ID: 20120424
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
